Literature DB >> 2966017

Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction.

E J Topol1, R M Califf, B S George, D J Kereiakes, D Rothbaum, R J Candela, C W Abbotsmith, C A Pinkerton, D C Stump, D Collen.   

Abstract

To determine whether tissue-type plasminogen activator (t-PA) and urokinase (UK) act synergistically to achieve coronary thrombolysis, incremental doses of both drugs were infused intravenously over 60 min. In 146 consecutive patients treated 3.0 +/- 1.0 hr from symptom onset, coronary angiography was performed 90 min after the start of the infusion and at 7 days. The groups of patients treated by different dose regimen were as follows: group I, 14 patients treated with t-PA 25 mg and UK 0.5 million U; group II, 20 patients given t-PA 25 mg and UK 1.0 million U; group III, 24 patients given t-PA 1.0 mg/kg and UK 0.5 million U; group IV, 33 patients treated with t-PA 1.0 mg/kg and UK 1.0 million U; and group V, 55 patients given t-PA 1.0 mg/kg and UK 2.0 million U. In groups I and II, patency of the infarct-related vessel at 90 min was only 36% and 42%, respectively. With 1 mg/kg t-PA and increasing doses of UK (groups III to V), patency ranged from 72% to 75% (overall 73%). Repeat catheterization at 7 days demonstrated reocclusion in groups III to V in 10 of 110 (9%). The patency and reocclusion rates in groups III to V were not significantly different from those in our previous study of 386 patients treated with t-PA alone (150 mg over 6 to 8 hr). In that study the patency rate of the infarct-related vessel at 90 min was 75% (p = .66) and reocclusion occurred in 15% (p = .11).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2966017     DOI: 10.1161/01.cir.77.5.1100

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  16 in total

Review 1.  Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction.

Authors:  M P Hudson; A B Greenbaum; R A Harrington; E M Ohman
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

Review 2.  Advances in thrombolytic therapy.

Authors:  M Verstraete
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

Review 3.  Answers to complex questions cannot be derived from "simple" trials.

Authors:  E J Topol; R M Califf
Journal:  Br Heart J       Date:  1992-10

Review 4.  Cardiology.

Authors:  L D Smith; D J Coltart
Journal:  Postgrad Med J       Date:  1990-04       Impact factor: 2.401

5.  French multicenter trial of anistreplase versus heparin in acute myocardial infarction.

Authors:  H Lardoux; Y Louvard; D de Vernejoul; C Picot; M Baudet; M Hiltgen; M Houplon; J Ponsonnaille; M Richard; R Luccioni
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

6.  Rescue PTCA Following Failed Thrombolysis and Primary PTCA: A Retrospective Study of Angiographic and Clinical Outcome.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

7.  Implications of the GUSTO trial for thrombolytic therapy.

Authors:  F Van de Werf
Journal:  Drugs       Date:  1996-09       Impact factor: 9.546

8.  Construction of a literature database and its use to provide probabilities for decision-analytic models of thrombolytic therapy.

Authors:  J F Murphy; N L Jain; C A Romero; M G Kahn
Journal:  Proc Annu Symp Comput Appl Med Care       Date:  1994

Review 9.  New strategies in the development of thrombolytic agents.

Authors:  H R Lijnen; D Collen
Journal:  Blut       Date:  1988-10

10.  After thrombolytic therapy: angiography, angioplasty, or surgery?

Authors:  M L Stadius
Journal:  Tex Heart Inst J       Date:  1990
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.